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Influenza viruses still constitute a real public health problem today. To cope with the
emergence of new circulating strains, but also the emergence of resistant strains to
classic antivirals, it is necessary to develop new antiviral approaches. This review
summarizes the state-of-the-art of current antiviral options against influenza infection,
with a particular focus on the recent advances of anti-influenza drug repurposing
strategies and their potential therapeutic, regulatory and economic benefits. The review
will illustrate the multiple ways to reposition molecules for the treatment of influenza,
from adventitious discovery to in silico-based screening. These novel antiviral molecules,
many of which targeting the host cell, in combination with conventional antiviral agents
targeting the virus, will ideally enter the clinics and reinforce the therapeutic arsenal to
combat influenza virus infections.
Keywords: influenza virus, antivirals, antiviral resistance, drug repurposing, drug repositioning, drug discovery,
drug combination, transcriptional profiling
INFLUENZA VIRUSES, A LONG-LIVED THREAT
FOR POPULATIONS
“A piece of bad news wrapped up in a protein,” definition of a virus by Sir Peter Medawar.
Despite its apparent blandness for the collective mindset of an important portion of the society, the
intrinsic morbidity and mortality as well as the related deaths because of bacterial superinfections
or exacerbation of chronic illnesses, make of influenza infections a major and recurrent global
public health concern. Indeed, human influenza type A and B viruses are responsible for annual
flu epidemics marked by up to 1 billion infections, 3–5 million severe cases and 300,000–650,000
deaths worldwide, with an huge economic burden in terms of medical visits, hospitalizations,
work/school absenteeism. and productivity loss (1–3). As members of the Orthomyxoviridae
family, influenza viruses (type A, B, C, or D) are enveloped viruses harboring a negative-sense
single-stranded RNA segmented genome. In such segmented nature of the viral genome resides the
capacity of influenza viruses to form new reassortant strains following the concomitant infection of
a host with more than one strain of human, and/or animal origin, a phenomenon so far observed
only among type A influenza viruses [reviewed in (4)]. Owing to viral reassortment, the genetic
baggage of progeny viruses does not exactly match that of one of the “parental” strains but a
combination of both. Depending on the specific combination of genetic segments, and notably
in the case of a human influenza strain acquiring the Hemagglutinin (HA) and/or Neuraminidase
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(NA) major surface antigens from animal origin, reassortment
events can result in an antigenic shift, defined as the generation
of a new virus with antigenic properties drastically different
from those of the circulating strains. Should this new variant
be sufficiently antigenically different to escape the repertoire
of pre-existing immunity in the population, it might rapidly
disseminate and replace the circulating strains, hence triggering
a global influenza pandemic. Although relatively rare–three
veritable pandemics occurred during the 20th Century and one
so far in the twenty-first century–the outbreak of pandemics
is a quite unpredictable event that might entail potentially
devastating effects [reviewed in (5)], particularly considering the
contemporary state of affairs regarding global transportation and
trade, migration, and the narrowing interface between rural and
overcrowded urban areas.
Influenza vaccination constitutes the most effective strategy to
prevent seasonal flu and its clinical complications, mainly among
high-risk populations such as very young children, the elderly,
pregnant women, immunocompromised patients as well as
people with obesity, diabetes, or cardiorespiratory comorbidities
(6, 7). Nevertheless, current flu vaccination still presents several
limitations that make it fall short of expectations in terms of
effectiveness. The short duration of vaccine-induced immunity
coupled with the intrinsic antigenic drift of influenza viruses
resulting from the gradual accumulation of point mutations in
the antigenic sites of the HA (and to a lesser extent the NA)
surface protein underscore the need of the annual reformulation
of vaccine composition. Moreover, the length of the current
vaccine manufacturing process (at least 6 months to produce
sufficiently large vaccine quantities) demands continual strain
selection to be done approximately 8 months before the next
flu season (6, 8). Should an antigenic drift occur during
this time window, the possibility of a mismatch between the
vaccine composition and circulating strains might negatively
affect protection. Even in the absence of seasonal mismatches
or the emergence of pandemic strains, insufficient vaccine
coverage and suboptimal uptake in specific target groups (i.e., the
elderly or the immunocompromised) also compromise vaccine
effectiveness. Furthermore, despite the recent progress made in
the pursue of the “Holy Grail” of a universal influenza vaccine
that can provide broader, long-lasting protection against both
matching, and antigenically diverse influenza strains (9, 10), their
clinical effectiveness remains to be evaluated, hence highlighting
the need of complementary therapeutic approaches to manage
influenza infections.
Besides vaccination, antiviral drugs represent the other pillar
for the control of seasonal influenza epidemics and play a central
role as major prophylactic and therapeutic agents in the event
of a pandemic outbreak. In that regard, this review summarizes
the state-of-the-art of current antiviral options against influenza
infection, with a particular focus on the recent advances of
anti-influenza drug repurposing strategies and their potential
therapeutic, regulatory and economic benefits. This review
presents examples of the multiple ways to reposition molecules
for the treatment of influenza, from adventitious discovery to in
silico-based screening. These novel antiviral candidates, many of
which target the host cell, could also be used in combination
with conventional virus-targeted antiviral agents in order to
reinforce our very limited therapeutic arsenal against influenza
virus infections.
CURRENT ANTIVIRAL OPTIONS FOR
TREATING INFLUENZA INFECTIONS
As mentioned above, antivirals are key players in pandemic
preparedness programs, being the first choice for the treatment
of infected patients as well as for preventive post-exposure
prophylaxis of those potentially exposed to the new virus,
especially during the initial pandemic period in which no vaccine
is available. Antivirals are as well important in the normal
seasonal setting. Although their use is mostly focused on the
treatment of severely ill patients and the immunocompromised,
some countries, including the USA and Japan, regularly resort
to antivirals for the management of uncomplicated influenza in
otherwise healthy patients (11, 12). To date, only two classes
of antiviral agents are globally approved and available for
the treatment of influenza infections: M2 ion-channel blockers
and neuraminidase (NA) inhibitors. The first class includes
adamantane derivatives, amantadine and rimantadine, which
inhibit proton conductivity of the M2 ion channel of influenza
A viruses hence preventing the viral uncoating step of the viral
replication cycle. Nevertheless, although quite efficient in their
early days, widespread dissemination of the S31N (and to a much
lesser extent V27A) M2 resistance mutation in post-2006 H3N2
and post-2009 H1N1 circulating strains prompted the WHO
to remove both amantadine and rimantadine from the list of
recommended anti-influenza agents for clinical use, in 2009 (6).
As a result, NA inhibitors stand as the only influenza antivirals
currently recommended by the WHO (13).
NA inhibitors are competitive analogs of sialic acid, the
preferred influenza receptor on the host cell’s surface. By
binding to the broadly conserved active site of the NA, NA
inhibitors interfere with the sialidase enzymatic activity of
the viral protein, which is essential for the release of newly
formed progeny viruses from the infected cell, hence preventing
the spread of infection to the rest of the respiratory tissue
(14). Three NA inhibitors are currently licensed worldwide
for the treatment of influenza A and B infections: oseltamivir,
zanamivir, and peramivir. Oral oseltamivir (administered as
its prodrug oseltamivir phosphate) is the most largely used
of the three, whereas inhaled zanamivir is not recommended
for very young children nor for individuals with underlying
respiratory conditions, and intravenous peramivir is prioritized
in hospitalized patients that cannot receive oral treatment (15).
Additionally, inhaled laninamivir, a single-dose long lasting NA
inhibitor, is approved in Japan for the prevention and treatment
of influenza A and B in both adult and pediatric patients (16). It
is important to note that some degree of skepticism is still present
regarding the real efficacy of NA inhibitors, notably following
the 2014’s Cochrane clinical meta-analysis that reported only a
minimal shortening of influenza symptoms in children and adults
with uncomplicated influenza but not in hospitalized patients
(17). Nevertheless, actual evidence-based consensus points to
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a moderate efficacy of NA inhibitor treatment in reducing
symptom duration, pneumonia, hospitalization and mortality,
especially when administered within 48 h from symptom onset
(18, 19). Conversely, delayed treatment initiation is associated
with compromised efficacy but may yet be beneficial in at-
risk patients. Moreover, the emergence of NA inhibitor-resistant
virus variants is a matter of concern, with particularly higher
frequencies among children and the immunocompromised (20).
The H275Y NA substitution is the main mutation responsible for
both oseltamivir and peramivir resistance in H1N1 viruses while
R292K and E119V are the most commonly reported in H3N2
viruses, these latter two also conferring reduced susceptibility
to zanamivir and laninamivir (17, 21). Even if nowadays the
prevalence of drug-resistance in circulating strains is quite low
(≤1%), evidence form pre-2009 seasonal strains has proved
that, given the appropriate conditions, resistance could rapidly
disseminate to attain a prevalence of 90–100% (17, 21). In that
regard, the relatively recent detection of localized clusters of NA
inhibitor-resistant H1N1pdm09 viruses harboring the H274Y
mutation combined or not with I222R/V NA substitutions (22,
23) strengthens the importance of continuous surveillance.
In addition to M2 ion channel blockers and NA inhibitors,
two small molecules that target the viral RNA-dependent RNA
polymerase, favipiravir and baloxavir marboxil, are undergoing
clinical evaluation in the US and Europe but already obtained
approval by Japanese Health authorities. Favipiravir is a
nucleoside analog that acts as a competitive inhibitor of viral
polymerase substrate, approved since 2014 for the treatment of
influenza infections with newly emerging strains and/or resistant
to other antiviral agents. However, despite the apparent high
threshold for drug resistance (24) and broad-spectrum antiviral
potential notably validated in the context of recent Ebola virus
outbreaks (25), recent results of Phase II/III randomized trials
on its therapeutic efficacy against uncomplicated influenza were
not completely conclusive (26). Baloxavir marboxil is a selective
inhibitor of the cap-dependent endonuclease activity of the
influenza viral PA polymerase subunit (27), therefore interfering
with the cap-snatching activity of the viral polymerase complex.
In that regard, a very recent report disclosed for the first
time the results of two randomized (Phases II and III) clinical
trials evaluating the efficacy of a single-dose oral treatment
with baloxavir marboxil in otherwise healthy outpatients with
acute uncomplicated influenza, compared with placebo and a
regular 5-day treatment with oseltamivir (28). Overall, baloxavir
marboxil and oseltamivir moderately reduced the time to
symptom alleviation compared to placebo, while the former
outperformed the two others in reducing viral loads. These
results prompted the US Food and Drug Administration (FDA)
to approve Xofluza R© (baloxavir marboxil) for the treatment
of acute uncomplicated influenza in patients 12 years of age
and older who have been symptomatic for no more than 48 h
(29). Nevertheless, this first antiviral flu treatment with a novel
mechanism of action approved by the FDA in nearly 20 years
does not seem to escape the problem of all other virus-targeted
anti-influenza agents. The emergence of virus variants (mostly
due to the I38T/M PA amino acid substitutions) conferring
significant levels of reduced susceptibility to baloxavir marboxil
was observed in up to 9.7% of the patients receiving the drug
(28, 30).
Overall, Table 1 summarizes the main characteristics of
the abovementioned currently available antiviral options for
influenza. Such limited therapeutic arsenal coupled with the
recurrent risk of emerging drug-resistance highlights the obvious
unmet need of novel approaches to complement existing
therapies with new anti-influenza drugs.
WHAT IS DRUG REPURPOSING?
“The most fruitful basis for the discovery of a new drug is to
start with an old drug,” famously stated the 1998 Nobel Prize in
Physiology and Medicine Laureate, Sir James Black.
Despite the enormous scientific and technological advances that
the field of biomedical research has witnessed in the last 20–30
years, this scenario failed to efficiently translate into significant
improvement on the success rate of the classic “from the bench to
the bedside” target-centered, mechanistically biased de novo drug
discovery process (38). Indeed, with an almost unchanged total
number of 25–30 novel molecules out of the approximately 50
new drugs yearly approved by the FDA (39), biopharmaceutical
experts estimate that only 12% of drug candidates that make it
into Phase I clinical trials receive the final green light (40). In
other words, of 5,000–10,000 compounds that come from classic
drug discovery, only one is likely to be approved. The causes of
this phenomenon are multifactorial, including the targeting of
more intricate diseases, limitations of reductionist experimental
models to reproduce biological complexity, increased regulatory
stringency, tolerability issues, and unexpected side effects.
Altogether, the total R&D process leading to the introduction of
a new drug in the market demands on average 13–15 years and
between U$S 1.5 and 2.6 billion (40–42).
In this context, drug repurposing stands as a worthwhile
attractive alternative to fill part of this so-called innovation
gap. Drug repurposing, also termed drug repositioning, defines
the process of identifying and validating a new therapeutic
indication for an existing or developmental drug (38, 42, 43).
The basis of drug repurposing relies on bypassing long, risky
and expensive preclinical and early clinical evaluation stages by
focusing on available extensive human clinical, pharmacokinetics
and safety data as the starting point for further development
(Figure 1). An extended definition could also include not only
already marketed drugs but also “sleeping” candidates that
have seen their development abandoned in advanced phases of
clinical evaluation (e.g., Phase II/III trials) due to non-satisfactory
efficacy for their first intended medical use, which might find
a second life in a novel therapeutic indication Noteworthy,
repurposing arguably accounts for 30% of the new drug products
approved by the FDA (44).
In practice, the concept of drug repurposing represents a
broad term encompassing many different, though not mutually
exclusive, experimental approaches to recognize potential new
applications outside the scope of the original medical indication
(42), including:
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TABLE 1 | Currently approved drugs for the treatment of influenza viral infections.
International
non-proprietary
name
Pharmaceutical
brand names
(examples)
Antiviral class Antiviral activity Clinical indication Resistance
reported
Discovery/
Reference
Amantadine
hydrochloride
Mantadix
Symmetrel
Symadine
Osmolex ER
M2 ion-channel
blockers
Blocks influenza virus uncoating
and entry into host cell
High risk old adults and children
Prophylaxis
Or treatment 24/48 post
symptoms appearance
YES 1963
(31)
Rimantadine
hydrochloride
Roflual
Flumandine
1969
(32)
Oseltamivir phosphate Tamiflu NA inhibitors Sialic acid structural analog,
competitive inhibitor of the
influenza viral neuraminidase
substrate
Children, adolescent and adults
48 h from symptom onset
YES 1998
(33)
Zanamivir Relenza Children and adults
≥5 years (prophylaxis)
≥7 years (treatment)
48 h from symptom onset
1993
(34)
Peramivir Rapivab
Peramiflu
Rapiacta
Children, adolescent and adults
intravenous peramivir is prioritized in
hospitalized patients that cannot
receive oral treatment
48 h from symptom onset
2000
(35)
Laninamivir octanoate Inavir Children and adults
inhaled laninamivir
Prevention adults and
pediatric patients
2000
(36)
Favipiravir Avigan Polymerase
inhibitor
Nucleoside analog, competitive
inhibitor of viral RNA-dependent
RNA polymerase substrate
Limited to cases in which
other influenza antiviral drugs are
ineffective or not sufficiently effective
YES 2002
(37)
Baloxavir marboxil Xofluza Selective inhibitor of the
cap-dependent endonuclease
activity of the influenza viral PA
polymerase subunit
Treatment of acute uncomplicated
influenza in patients 12 years of age
and older who have been
symptomatic for no more than 48 h
2018
(27)
FIGURE 1 | From the bench to the bedside: comparison between de novo drug development and drug repurposing. De novo (classic) drug development constitutes
a time-consuming and expensive process. From initial discovery to market, it generally takes 13–15 years and costs up to US$ 2 billion, with a very low success rate
(10%). In contrast, drug repurposing approaches offer several advantages. Indeed, the time frame from discovery to market is shorter (5–11 years), less expensive
(US$ 350 million), and with a higher success rate (30%), mostly because a large part of preclinical and clinical testings (e.g., safety, formulation, posology) have been
already performed for the drug’s initial therapeutic indication (41, 42).
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Serendipitous Observations
Some of the best-known success stories of drug repurposing
have their starting point on serendipitous observations recorded
in the context of either preclinical models of disease or pre-
/post-approval clinical trials, leading to a subsequent rationalized
evaluation and validation of the new treatment potential (41).
Thalidomide and sildenafil are two examples of such key
observations. The first one was initially introduced as an anti-
nausea for pregnant women but had to be rapidly removed from
the market due to its teratogenicity. Further research enabled
this molecule as well as some derivatives to be repurposed for
the treatment of leprosy and multiple myeloma (45). Sildenafil,
on the other hand, never reached the market for its originally
intended use in the treatment of hypertension but the observed
side-effects on erectile dysfunction ended in its approval in under
the commercial name of Viagra R©. More recently, sildenafil found
a third life under the commercial brand of Revatio R© for the
treatment of pulmonary hypertension (46).
Target-Based Repurposing
Although serendipitous observation has historically proved its
usefulness, the intrinsic necessity of the casual observation
of an unintended and usually infrequent second benefit
poses a significant hurdle for exploiting the full potential
of drug repurposing, for which more controlled, systematic
methodologies are needed. Target-based repurposing relies on
having previous knowledge of the specific molecular or cellular
determinant/function target recognized by the drug intended to
be repurposed. If new research finds out that target is plays an
important role in a condition or disease other than the original
indication, there is a potential for repurposing. Of note, the target
might but not necessarily has to play the same role in both
conditions. For example, in the case of the previously mentioned
favipiravir, the drug plays the same role as viral RNA polymerase
inhibitor against both influenza and Ebola viruses. On the other
hand, the Abelson tyrosine-protein kinase 2 (Abl2), target of
the anticancer drug imatinib, has been found to be required for
efficient fusion and release of severe acute respiratory syndrome
coronavirus (SARS-CoV) and Middle East respiratory syndrome
coronavirus (MERS-CoV) pseudovirions into the cytoplasm of
the infected cell, a key step for viral replication (47).
An alternative scenario of target-based repurposing can
happen when a particular drug of known mechanism of action is
found to have a newmolecular/cellular target, and this previously
unrecognized second target is associated with a different disease.
The molecule is therefore said to present polypharmacology-
related features, meaning the capacity to act on multiple targets
(48, 49). Polypharmacological phenomena includes both a single
drug acting on multiple targets of a unique disease pathway, or
a single drug acting on multiple targets pertaining to multiple
disease pathways (50). In fact, polypharmacology is usually
responsible for treatment toxicity or other undesirable adverse
events, but some of these “side-effects” might also lead to drug
repurposing, as further exemplified in the next sections. During
the last decade, an increasing number of studies converged
on proposing that many drugs, initially designed for a unique
therapeutics target, are in fact expected to hit on average between
6 and 13 different targets (51, 52).
Phenotypic Screening
Onemajor limitation of the target-based drug repurposingmodel
relies on its dependence on the existing scientific knowledge of
the drug/disease mechanism(s) of action/pathology as well as
on potential alternative targets, which is usually incomplete. In
other words, we cannot fully anticipate the repurposing potential
of a drug unless we have characterized its molecular/cellular
target(s), or if we do not know that a given drug target plays
an important role on a particular disease. Phenotypic screening
of bioactive molecule libraries in different experimental cell-
based or in vivo disease models without the need of a priori
knowledge or consideration of the target and/or mechanism
of action the candidate was designed to modulate can provide
valuable contribution to overcome this constraint (53). Indeed,
despite this approach has been questioned due to the fact
that the expected altered phenotype readout as a surrogate of
an exploitable biological effect induced by the drug candidate
might account for an important number of false positive
“hits,” it is nonetheless true that the contribution of high-
throughput phenotypic screening to first-in-class small molecule
drug discovery exceeded that of target-based approaches (54,
55). In that regard, many well-annotated collections of small-
molecule libraries could be readily made available through
different collaborative and/or commercial partnerships in order
to accelerate drug repurposing through hypothesis biased or
unbiased phenotypic screening [reviewed in (54–57)].
In silico-Assisted Repurposing
With the advent of big data and systems biology, computer-based
approaches are gaining increasing acceptance in the field of drug
discovery, and drug repurposing is not an exception. Besides the
inclusion of constantly emerging “omics” (e.g., transcriptomic,
proteomic, metabolomic) data to expand our current knowledge
of drug/disease-associated mechanisms, in silico data mining
and modeling tools have pushed our capacity to analyze data
to the next level (58–60). These in silico methods include the
screening of chemical, biological, and text databases, analysis of
quantitative structure-activity relationships, pharmacophores,
homology models, and other molecular modeling approaches
as well as network analysis of biological functions, machine
learning and almost any other analysis tools that include
using a computer (61–64). In that regard, proper mining of
biological, chemical and clinical datasets, has proved effective
in unveiling novel relationships (65, 66). Moreover, another
level of complexity can be added by combining, for example,
epidemiologic information obtained in-house and/or from
publicly available literature databases with in vitro experimental
molecule screenings with the aim to identify novel indications,
as in the case of digoxin and prostate cancer (67, 68). Indeed,
the real power of computer-assisted drug repurposing resides
on adopting an integrative strategy that combines the predictive
and analytic capacity of in silico tools with some of the target
biased or unbiased experimental evaluation/validation methods
previously mentioned. This “systems pharmacology” approach
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(69–71) across the boundaries of traditional disciplines would
put researchers in a better-informed position to design more
comprehensive repurposing strategies with more effective
predictive capacity and, hopefully, improved candidate
success rates.
THE EMERGENCE OF DRUG
REPURPOSING APPROACHES IN THE
FIELD OF ANTIVIRAL DRUG DISCOVERY
These last 10 years, there has been a remarkable growing interest
for drug repurposing in the field of antiviral drug discovery,
fueled by the incontestable reality of many known viral infections
still lacking specific treatment. This interest is inversely correlated
with the very low number of classic antiviral molecules that
have been market-approved these last 5 years, mostly for the
treatment of hepatitis C virus or HIV-related pathologies (72).
The best example of antiviral drug repurposing approaches are
emerging viruses such as Ebola, Zika virus or MERS-CoV, for
which there is an urgent and cost-effective need for therapeutics
solutions. Indeed, to rapidly propose a solution in the context
of a viral outbreak, one interesting approach consists to look at
the available pharmacopeia used to treat pathogens. For example,
chloroquine, a major antimalarial drug, has been proposed for
the treatment of filoviral infections, and more largely for the
treatment of other emerging pathogens, as it targets endosomal
acidification, a pivotal step in the replication cycle of a large
number of viruses (73, 74). Another interesting illustration is
the previously cited example of favipiravir, which proved its
repurposing potential for the treatment of Zika or Ebola viral
infections (25, 43, 75).
DRUG REPURPOSING FOR INFLUENZA
VIRAL INFECTION
As mentioned before, the intrinsic ever-evolving nature of the
virus, high transmissibility, host promiscuity, suboptimal vaccine
efficacy, limited antiviral arsenal, and zoonotic, and pandemic
potential are more than convincing factors to consider influenza
viruses as attractive targets for drug repurposing. Despite many
interesting omics-based approaches (76) or high-throughput
screening of specific drug libraries, such as kinase inhibitors (77),
no anti-influenza agent issued from drug repurposing has yet
reached regulatory market approval. However, advances made
during the last years forecast optimism. The following selected
examples constitute a very good illustration of the diversity and
capabilities of drug repurposing strategies for influenza infection.
An exhaustive list of anti-influenza candidates issued from drug
repurposing approaches is presented in Table 2.
The case of statins is arguably the best-known example of anti-
influenza repurposing issued from clinical observations. In the
early 2000s, clinicians observed that besides the cardioprotective
activity of statins, these hydroxyl methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitors approved for their use as
cholesterol metabolism regulators could have pleiotropic anti-
inflammatory and immunomodulatory effects, which could be of
benefit to improve survival of patients with severe influenza (78–
80). Although many mouse and observational studies account
for the protective role of statins in pneumonia, most in vivo
studies reported so far failed to clearly demonstrate such a
beneficial effect in the specific context of influenza infection
(99–102). On the other hand, a few but not all observational
studies highlighted an association between statin treatment with
up to 41% reduction of 30-day all-cause mortality in patients
hospitalized with laboratory-confirmed seasonal influenza (103–
105). A randomized placebo-controlled Phase II clinical trial
(NCT02056340) aimed at evaluating the potential effect of
atorvastatin to reduce the severity of illness in influenza-infected
patients is currently undergoing.
Nitazoxanide is another illustration of a serendipitous
repurposing approach, and probably one of the most promising
examples. Nitazoxanide is a thiazolide anti-infective initially
licensed for the treatment of parasitic infections, for which anti-
influenza properties were first documented by Rossignol et al.
(81). Interestingly, the proposed mode of action of nitazoxanide
toward influenza is clearly distinct to that for which it was
designed in its initial indication, acting at the post-translational
level by selectively blocking the maturation of the viral
glycoprotein HA, with a consecutive impact on its intracellular
trafficking and insertion into the host plasma membrane (81,
106). This drug presents potent antiviral activity against a
large panel of circulating strains (82). The effectiveness of
nitazoxanide in treating patients with non-complicated influenza
was successful in a Phase IIb/III trial (107) and is currently being
assessed in a Phase III clinical trial (NCT01610245).
BAY81-8781/LASAG (D, L-Lysine acetylsalicylate-glycine), a
modified version of the anti-inflammatory drug acetylsalicylic
acid (ASA) licensed for intravenous and inhalation delivery, is
currently investigated as an anti-influenza treatment as a result
of a mixed serendipitous and target-based repurposing strategy.
It was initially shown that ASA had interesting antiviral effects
against influenza viruses in vitro and in vivo via the inhibition
of the NF-kB activating kinase IkkB, which negatively impacts
influenza vRNP transport and release of infectious viral particles
(108–110). However, due to the pharmacokinetic limitations
of ASA, the LASAG modified version with improved stability
and tolerability was developed. Like ASA, this molecule also
demonstrates antiviral activity against several human and avian
influenza viruses in vitro. In a mouse infection model, inhalation
of LASAG resulted in reduced lung viral titers and protection
of mice from lethal infection (85). More recently, a Phase II
proof-of-concept study comparing LASAG versus placebo in
patients with severe influenza (all patients receiving Tamiflu
as standard of care treatment) demonstrated that aerosolized
LASAG improved the time to symptom alleviation compared to
placebo, despite the absence of a statistically significant reduction
of viral load in LASAG-treated group (86).
Naproxen constitutes a nice example of in-silico & target-
based strategy for the identification of new antivirals. Lejal et al.
used a structure-based modeling approach to identify drugs of
interest directed against the nucleoprotein (NP) of influenza A
virus, using the X-ray structure of the RNA-free NP of H1N1
as prototype. An in-silico screening, focused of a defined specific
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site of NP structure, has identified naproxen, a known inhibitor
of inducible cyclooxygenase type 2 (COX-2) commonly used as
non-steroidal anti-inflammatory drug. This identified molecule
has shown antiviral properties against influenza A virus in vitro
and in vivo (94). More recently, naproxen analogs with improved
efficacy have been developed, showing high level of inhibition
of both NP-RNA and NP-polymerase subunit PA complexes,
without parallel inhibition of COX-2 (111, 112). Interestingly, in
contrast to other examples of drug repurposing strategies, the
example of naproxen remains virus-targeted and future works
will determine if this drug will present the sameAchille’s heel than
classic antivirals regarding selection of antiviral resistance.
The last two examples of this chapter are midodrine and
diltiazem, that we identified as influenza antivirals in the context
of an in-silico assisted strategy based on transcriptional profiling.
An emerging approach in drug repurposing is based on signature
matching, which consists of comparing a specific characteristic
of a drug–its cellular signature–to that of a disease (42). This
approach, mostly based on transcriptomic data, was successfully
exploited to identify drug repurposing opportunities in a large
range of therapeutics areas, and notably in the field of oncology
and rare diseases (42). Our group was the first to transpose
this approach to the field of viral infectious diseases, thanks
to the development and democratization of DNA-microarray
and more recently RNAseq techniques. In a proof-of-concept
study using an in vitro model of infection, we postulated that
host global gene expression profiling can be considered as a
“fingerprint” or signature of any specific cell state, including
during infection or drug treatment, and hypothesized that
the screening of databases for compounds that counteract
virogenomic signatures could enable rapid identification of
effective antivirals (97). Among the molecules identified in
silico, midodrine, an adrenergic alpha receptor agonist widely
used to treat hypotension, demonstrated very interesting in
vitro antiviral activities (97). These results prompted the
Phase II clinical evaluation of midodrine (NCT01546506)
for the treatment of uncomplicated seasonal flu in primary
care centers.
Based on this previous proof-of-concept obtained from in
vitro gene expression profiles, we further improved the strategy
by analyzing upper respiratory tract clinical samples collected
from a cohort of influenza A(H1N1)pdm09-infected patients
and determined their respective transcriptomic signatures. We
then performed an in-silico drug screening and identified a
list of candidate bioactive molecules with signatures anti-
correlated with those of the patient’s acute infection state.
The potential antiviral properties of selected market-approved
molecules were firstly validated in vitro, and the most effective
compounds were further compared to oseltamivir for the
treatment of influenza A(H1N1)pdm09 virus infections in mice
and in a physiological in vitro model of reconstituted human
airway epithelia (MucilAirTM). These results notably highlighted
diltiazem, a calcium channel blocker used as an anti-hypertensive
drug, as a very promising repurposed host-targeted inhibitor
of influenza infection (98). An ongoing French multicenter
randomized clinical trial is investigating the effect of diltiazem-
oseltamivir bitherapy compared with standard oseltamivir
monotherapy for the treatment of severe influenza infections in
intensive care units (FLUNEXT trial NCT03212716).
VIRUS-TARGETED vs. HOST-TARGETED
THERAPY, WHY NOT BOTH?
“Two are better than one, because they have a good return for their
labor” Ecclesiastes 4:9-10.
The concept of antiviral combination therapy was originally
pioneered for antiretroviral treatments, with the primary goal of
preventing or at least delaying the emergence of drug resistance
via the targeting of multiple steps of the viral cycle (113).
Another expected complementary goal is to obtain additive or
synergistic effects by combining drugs, a “double-trigger” effect,
to increase effectiveness and/or reduce dosage. In the context of
influenza infections, the combination of classic antivirals, mostly
NA inhibitors, was explored by several research groups, including
ours, with relatively mixed conclusions. For example, in a mouse
model, the combination of oseltamivir with zanamivir was shown
to be not superior to zanamivir monotherapy in the context of
influenza A(H3N2) or A(H1N1)pdm09 infection (114). A clinical
trial was conducted during the A(H1N1)pdm09 pandemic
in 2009-2010 (COMBINA trial NCT00830323) and failed
to demonstrate whether oseltamivir/zanamivir combination
therapy improved or reduced the effectiveness of oseltamivir
alone in the treatment of influenza infections in community
patients (115). Other clinical investigations have shown a greater
effectiveness of such combination therapy to reduce influenza
transmissibility (116).
As most alternative antiviral strategies for the treatment of
influenza infections, including those related to drug repurposing
and targeting the host instead of viral determinants, an
emerging trend consists to propose innovative therapies that
combine classic antivirals with host-targeting drugs, which
starts to show promising results (87). For example, Belardo
et al. have demonstrated, in cell culture-based assays using
different human and avian models, that the combination
of NA inhibitors and nitazoxanide presents synergistic
anti-influenza effects (117). Convincing results were also
obtained using a combination treatment including naproxen.
In a clinical trial enrolling hospitalized patients infected by
influenza A(H3N2), combination therapy with naproxen,
oseltamivir, and clarithromycin showed improved efficacy in
terms of hospital stay duration and patient mortality, when
compared to oseltamivir treatment alone (118). In the context
of the evaluation of the antiviral activity of diltiazem in the
reconstituted human airway epithelium model MucilAirTM, our
group demonstrated that the diltiazem-oseltamivir combination
treatment conferred a greater reduction of apical viral titers
than that was measured with the same-dose monotherapy,
with a marked delay of viral production (98). An ongoing
French multicenter randomized clinical trial is investigating
the effect of diltiazem-oseltamivir bitherapy compared with
standard oseltamivir monotherapy for the treatment of
Frontiers in Immunology | www.frontiersin.org 8 March 2019 | Volume 10 | Article 531
Pizzorno et al. Drug Repurposing for Influenza Infections
severe influenza infections in intensive care units (FLUNEXT
trial NCT03212716).
Altogether, these results plead in favor of the use of drug
repurposing for the improvement of the current standard of
care anti-influenza therapy. In contrast to other technological
domains, the innovation is not necessary chasing and replacing
the established standard, and future works are still necessary to
investigate the real impact of these novel “host & virus-targeted”
multi-therapy approaches on the management and control of the
emergence of viral resistance.
CONCLUDING REMARKS
“We do not need to find new drugs; rather we need to find the
patients who can benefit from existing drugs” the saying goes.
Although somehow exaggerated, this statement summarizes
pretty clearly the essence behind the drug repurposing initiative.
Finding new indications for already-existing drugs has many
benefits, mainly by improving cost-effectiveness, reducing risks,
and shortening time to market (37, 41). The purpose of this
review was to foster discussion on drug repurposing as an
option to complete and implement our current anti-influenza
therapeutic arsenal. We are facing an important need for
the development of novel antiviral strategies that improve
treatment effectiveness–especially in the case of severe diseases–
and that are less prone to selection for antiviral resistance. In
that regard, the identification and validation by different and
complementary means of repurposed drugs is incontestably of
great interest, notably in combination with current classic virus-
targeted inhibitors. In addition, the deposition of data, including
negative results, into public database should be encouraged, as it
would facilitate efforts to repurpose licensed or orphaned drugs,
and consecutively increase our chances to find new efficient
antiviral drugs. With a growing number of academic groups and
pharmaceutical companies working on this emerging field, we
should most certainly see interesting progress and efficient novel
anti-influenza therapies reaching regulatory market approval in a
near future.
In the context of a globalized world facing major
vicissitudes including population dynamics, climate change
and the multiple emergence/re-emergence of zoonotic
viruses, the effectiveness and reaction force of the classic
de novo development of antivirals is challenged. Despite
inherent limits, drug repurposing offers a very large
palette of possibilities to rapidly and efficiently find new
antiviral drugs.
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